Bicalutamide dosages used in the treatment of prostate cancer

Prostate

Volumn 39, Issue 1, 1999, Pages 47-53

  Kolvenbag, Geert J C M ^a,b   Nash, Anthony ^b  

^a Zeneco Pharmaceutical   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antiandrogen; Casodex ; Combined androgen blockade; Monotherapy

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER THERAPY; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERANCE; HORMONAL REGULATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0033559910     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990401)39:1<47::AID-PROS8>3.0.CO;2-X     Document Type: Article

References (29)

1. Lunglmayr G. Casodex (ICI 176,334), a new nonsteroidal anti-androgen. Early clinical results. Horm Res [Suppl] 1989;32:77-81.
2. Newling DWW. The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase II study of Casodex. Eur Urol [Suppl] 1990;18:18-21.
3. Blackledge GRP. Clinical progress with a new antiandrogen, casodex (bicalutamide). Eur Urol [Suppl] 1996;29:96-104.
4. Blackledge GRP, Lowery K. Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate [Suppl] 1994; 5:34-38.
5. Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34:61-72.
6. Luo S, Martel C, LeBlanc G, Candas B, Singh SM, Labrie C, Simard J, Bélanger A, Labrie F. Relative potencies of flutamide and Casodex: preclinical studies. Endocr Rel Cancer 1996; 3:229-241.
7. Furr BJA. Relative potencies of flutamide and casodex. Endocr Rel Cancer 1997;4:197-202.
8. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987;113:7-9.
9. Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, Philibert D. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem 1994;48: 111-119.
10. Chandolia RK, Weinbauer GF, Behre HM, Nieschlag E. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. J Steroid Biochem Mol Biol 1991;18: 367-375.
11. Chandolia RK, Weinbauer GF, Simoni M, Behre HM, Nieschlag E. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat. Acta Endocrinol (Copenh) 1991;125:547-555.
12. Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology [Suppl] 1996;47:13-25.
13. Cockshott ID, Plummer GF, Cooper KJ, Warwick MJ. The pharmacokinetics of Casodex in laboratory animals. Xenobiotica 1991;21:1347-1355.
14. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol [Suppl] 1990; 18:10-17.
15. Brogden RN, Chrisp P. Flutamide - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer. Drugs Aging 1991;1:104-115.
16. Schultz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988;34: 633-666.
17. Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P. Longterm therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 1988;140:775-777.
18. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LH-RH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-508.
19. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 1996;47:26-28.
20. Kolvenbag GJCM, Blackledge GRP. Worldwide activity and safety of bicalutamide: a summary review. Urology [suppl]1996; 47:70-79.
21. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellhammer JJ, Kolvenbag GJCM. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997;50:330-336.
22. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 1995;28:215-222.
23. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995;46:849-855.
24. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 mg rnonotherapy vs. orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996;30:93-98.
25. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamerlain M, Carroll K, Gotting-Smith K, Blackledge GRP. Casodex (bicalutamide) 150 mg rnonotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51:389-396.
26. Tyrrell CJ, Kaisary AV, Iversen P, Andersond JB, Baerte L, Tammelaf T, Chamberlaing M, Websterh A, Blackledge G. A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-456.
27. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993;20:749-756.
28. Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate [Suppl] 1994;5:27-33.
29. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology [suppl] 1996;47:38-43.